Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilostazol

Drug Profile

Cilostazol

Alternative Names: OPC-13013; OPC-21; Pletaal; Pletal

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical; Pfizer
  • Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
  • No development reported Angina pectoris
  • Discontinued Coronary artery restenosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Sep 2017 No development reported - Phase-III for Angina pectoris (In the elderly, Treatment-experienced, In adults) in South Korea (PO)
  • 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top